Our results show that the multitargeted SRC TKI dasatinib significantly enhanced the efficacy of RET TKIs in RET fusion-positive (RET<sup>+</sup>) NSCLC and PTC cells. This evidence concerns the gene RET and non-small cell lung carcinoma.